Compare CFFI & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFI | VYGR |
|---|---|---|
| Founded | 1927 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.4M | 194.0M |
| IPO Year | 1996 | 2015 |
| Metric | CFFI | VYGR |
|---|---|---|
| Price | $72.85 | $3.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 1.9K | ★ 466.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | ★ 37.94 | N/A |
| EPS | ★ 8.29 | N/A |
| Revenue | ★ $140,841,000.00 | $10,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $71.77 |
| P/E Ratio | $8.79 | ★ N/A |
| Revenue Growth | ★ 10.63 | N/A |
| 52 Week Low | $53.14 | $2.65 |
| 52 Week High | $80.99 | $5.55 |
| Indicator | CFFI | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 51.04 |
| Support Level | $66.92 | $3.73 |
| Resistance Level | $72.90 | $4.43 |
| Average True Range (ATR) | 1.33 | 0.24 |
| MACD | -0.56 | 0.04 |
| Stochastic Oscillator | 19.37 | 58.26 |
C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum of its revenue from the Community Banking segment.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.